Dalgety, a UK-based EU-GMP certified medical cannabis cultivator, has today announced a new strategic partnership with Curaleaf Laboratories, a trusted name in cannabis medicine and pharmaceutical-quality cannabinoid innovation.
This collaboration is a significant step towards ensuring affordable, safe, and sustainable access to high-quality medical cannabis in the UK.
As the UK medical cannabis sector grows, so too does the need to build a responsible, resilient domestic supply chain, one rooted in quality, transparency, and trust.
For Dalgety, that means working not only with the right partners but also with those whose own networks reflect the same high standards. This partnership with Curaleaf reflects a shared vision for safeguarding the integrity of the UK medical cannabis system at a time when bad actors threaten to undermine patient and clinician confidence.
“Our goal at Dalgety has always been to put patients first, delivering consistent, effective medicine.” said James Leavesley, CEO of Dalgety.
“But to do that, we must tackle non-patient derived costs that inflate prices and damage trust. This partnership with Curaleaf allows us to reduce unnecessary layers in the supply chain, while maintaining (and in many cases raising) standards across cultivation, manufacturing, and distribution.”
https://businessofcannabis.com/dalgety-signs-strategic-partnership-with-curaleaf-laboratories/
